Direkt zum Inhalt
Merck

A facile approach to enhance antigen response for personalized cancer vaccination.

Nature materials (2018-03-07)
Aileen Weiwei Li, Miguel C Sobral, Soumya Badrinath, Youngjin Choi, Amanda Graveline, Alexander G Stafford, James C Weaver, Maxence O Dellacherie, Ting-Yu Shih, Omar A Ali, Jaeyun Kim, Kai W Wucherpfennig, David J Mooney
ZUSAMMENFASSUNG

Existing strategies to enhance peptide immunogenicity for cancer vaccination generally require direct peptide alteration, which, beyond practical issues, may impact peptide presentation and result in vaccine variability. Here, we report a simple adsorption approach using polyethyleneimine (PEI) in a mesoporous silica microrod (MSR) vaccine to enhance antigen immunogenicity. The MSR-PEI vaccine significantly enhanced host dendritic cell activation and T-cell response over the existing MSR vaccine and bolus vaccine formulations. Impressively, a single injection of the MSR-PEI vaccine using an E7 peptide completely eradicated large, established TC-1 tumours in about 80% of mice and generated immunological memory. When immunized with a pool of B16F10 or CT26 neoantigens, the MSR-PEI vaccine eradicated established lung metastases, controlled tumour growth and synergized with anti-CTLA4 therapy. Our findings from three independent tumour models suggest that the MSR-PEI vaccine approach may serve as a facile and powerful multi-antigen platform to enable robust personalized cancer vaccination.